Proteasome independent protein knockdown by small-molecule inhibitor for the undruggable lung adenocarcinoma
2019
Therapeutic target identification and corresponding drug development is a demanding task for the treatment of lung adeno-carcinoma, especially the most malignant proximal-proliferative subtype without druggable protein kinase mutations. Using a cell-SELEX-generated aptamer, we discovered a new tumor driver protein, leucine-rich pentatricopeptide repeat-containing protein (LRPPRC), which is specifically overexpressed in the most lethal subtype of lung adenocarcinoma. Tar-geted LRPPRC protein knockdown is a promising therapeutic strategy for the undruggable LUAD (lung adenocarcinoma). Nevertheless, LRPPRC is mainly located in mitochondria and degraded by protease. Current protein knockdown approaches, such as proteolysis-targeting chimeras (PROTACs), have limitations in their applications to the proteins degraded through proteasome-independent ways. Here, we designed an aptamer-assisted high-throughput method to screen small molecules which could bind to LRPPRC directly, disrupt the interaction of LRPPRC wi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
8
Citations
NaN
KQI